Azienda Ospedaliera Ordine Mauriziano Di Torino
Verified site
Turin, Italy
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying a type of cancer known as colorectal cancer, specifically in patients who have a high risk of the disease returning after initial treatment. The study is investigating the use of two medications, temozolomide and irinotecan, to see if they can help reduce the risk of cancer coming back. These medications are being tested in patients whose cancer cells have certain characteristics, such as being microsatellite stable and having a silenced gene called MGMT. The trial is called the ERASE-TMZ study.
The purpose of the study is to evaluate how effective the combination of temozolomide and irinotecan is in treating patients with this specific type of colorectal cancer. Participants in the study will receive these medications after they have completed standard chemotherapy, which usually includes a drug called oxaliplatin. The study will monitor patients to see if the cancer remains undetectable in their blood tests, which is a sign that the treatment might be working. Some patients will receive a placebo instead of the active medications to compare the results.
Throughout the study, patients will be regularly checked to ensure their safety and to monitor any side effects from the treatment. The study will also look at how long patients remain free of cancer and their overall survival. Additionally, researchers will collect information from patients about their quality of life during the study. This information will help determine if the treatment is not only effective but also tolerable for patients. The study aims to provide valuable insights into whether this combination of medications can be a beneficial treatment option for patients with this type of colorectal cancer.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
14 criteria
7 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Turin, Italy
Catania, Italy
Monserrato, Italy
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
RecruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
This medication is administered orally and is currently being studied for its effectiveness in treating certain types of colorectal cancer. It is primarily used in patients with specific genetic markers, such as MGMT silenced and microsatellite stable tumors, who have residual disease after standard chemotherapy. Temozolomide works by damaging the DNA of cancer cells, which prevents them from dividing and growing. It is classified as an alkylating agent, a type of chemotherapy drug.
This medication is given intravenously and is also under investigation for its role in treating colorectal cancer with specific genetic characteristics. It is used in patients who have persistent cancer markers in their blood after initial chemotherapy. Irinotecan acts by inhibiting an enzyme called topoisomerase I, which is necessary for DNA replication in cancer cells, thereby stopping their growth. It belongs to the class of drugs known as topoisomerase inhibitors.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.